J&J says its lung cancer drug combination keeps people alive longer
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to supplant AstraZeneca's blockbuster Tagrisso, a once-daily pill that has transformed the treatment of non-small cell lung cancer with EGFR mutations.
Combination extends survival vs. standard first-line therapy for advanced lung cancer
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with amivantamab-vmjw (Rybrevant,
J&J says cancer drug combination showed survival benefit over Tagrisso
Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.
Johnson & Johnson says its lung cancer drug significantly extended survival
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer patients.
Johnson & Johnson’s rybrevant plus lazcluze improve survival in lung cancer
Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from
Drug extends survival in lung cancer patients: J&J
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung cancer that has specific epidermal growth factor receptor mutations.
Cure Today1d
Rybrevant Plus Lazcluze Improves Survival for EGFR+ NSCLC
First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...
GlobalData on MSN2d
J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
FiercePharma3d
With key win over AstraZeneca's Tagrisso, J&J touts Rybrevant-Lazcluze combo as 'new standard of care'
Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...
STAT3d
Can an epilepsy drug do more than reduce seizures?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Genmab’s Strategic Positioning and Promising Clinical Data Drive Buy Rating with $50 Price Target
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Genmab (GMAB – Research Report). The associated price target ...